Cargando…

Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis

INTRODUCTION: Interventional ICU trials have followed up patients for variable duration. However, the optimal duration of follow-up for the determination of mortality endpoint in such trials is uncertain. We aimed to determine the most logical and practical mortality end-point in clinical trials of...

Descripción completa

Detalles Bibliográficos
Autores principales: Taori, Gopal, Ho, Kwok M, George, Carol, Bellomo, Rinaldo, Webb, Steven AR, Hart, Graeme K, Bailey, Michael J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750185/
https://www.ncbi.nlm.nih.gov/pubmed/19653888
http://dx.doi.org/10.1186/cc7988
_version_ 1782172222492770304
author Taori, Gopal
Ho, Kwok M
George, Carol
Bellomo, Rinaldo
Webb, Steven AR
Hart, Graeme K
Bailey, Michael J
author_facet Taori, Gopal
Ho, Kwok M
George, Carol
Bellomo, Rinaldo
Webb, Steven AR
Hart, Graeme K
Bailey, Michael J
author_sort Taori, Gopal
collection PubMed
description INTRODUCTION: Interventional ICU trials have followed up patients for variable duration. However, the optimal duration of follow-up for the determination of mortality endpoint in such trials is uncertain. We aimed to determine the most logical and practical mortality end-point in clinical trials of critically ill patients. METHODS: We performed a retrospective analysis of prospectively collected data involving 369 patients with one of the three specific diagnoses (i) Sepsis (ii) Community acquired pneumonia (iii) Non operative trauma admitted to the Royal Perth Hospital ICU, a large teaching hospital in Western Australia (WA cohort). Their in-hospital and post discharge survival outcome was assessed by linkage to the WA Death Registry. A validation cohort involving 4609 patients admitted during same time period with identical diagnoses from 55 ICUs across Australia (CORE cohort) was used to compare the patient characteristics and in-hospital survival to look at the Australia-wide applicability of the long term survival data from the WA cohort. RESULTS: The long term outcome data of the WA cohort indicate that mortality reached a plateau at 90 days after ICU admission particularly for sepsis and pneumonia. Mortality after hospital discharge before 90 days was not uncommon in these two groups. Severity of acute illness as measured by the total number of organ failures or acute physiology score was the main predictor of 90-day mortality. The adjusted in-hospital survival for the WA cohort was not significantly different from that of the CORE cohort in all three diagnostic groups; sepsis (P = 0.19), community acquired pneumonia (P = 0.86), non-operative trauma (P = 0.47). CONCLUSIONS: A minimum of 90 days follow-up is necessary to fully capture the mortality effect of sepsis and community acquired pneumonia. A shorter period of follow-up time may be sufficient for non-operative trauma.
format Text
id pubmed-2750185
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27501852009-09-25 Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis Taori, Gopal Ho, Kwok M George, Carol Bellomo, Rinaldo Webb, Steven AR Hart, Graeme K Bailey, Michael J Crit Care Research INTRODUCTION: Interventional ICU trials have followed up patients for variable duration. However, the optimal duration of follow-up for the determination of mortality endpoint in such trials is uncertain. We aimed to determine the most logical and practical mortality end-point in clinical trials of critically ill patients. METHODS: We performed a retrospective analysis of prospectively collected data involving 369 patients with one of the three specific diagnoses (i) Sepsis (ii) Community acquired pneumonia (iii) Non operative trauma admitted to the Royal Perth Hospital ICU, a large teaching hospital in Western Australia (WA cohort). Their in-hospital and post discharge survival outcome was assessed by linkage to the WA Death Registry. A validation cohort involving 4609 patients admitted during same time period with identical diagnoses from 55 ICUs across Australia (CORE cohort) was used to compare the patient characteristics and in-hospital survival to look at the Australia-wide applicability of the long term survival data from the WA cohort. RESULTS: The long term outcome data of the WA cohort indicate that mortality reached a plateau at 90 days after ICU admission particularly for sepsis and pneumonia. Mortality after hospital discharge before 90 days was not uncommon in these two groups. Severity of acute illness as measured by the total number of organ failures or acute physiology score was the main predictor of 90-day mortality. The adjusted in-hospital survival for the WA cohort was not significantly different from that of the CORE cohort in all three diagnostic groups; sepsis (P = 0.19), community acquired pneumonia (P = 0.86), non-operative trauma (P = 0.47). CONCLUSIONS: A minimum of 90 days follow-up is necessary to fully capture the mortality effect of sepsis and community acquired pneumonia. A shorter period of follow-up time may be sufficient for non-operative trauma. BioMed Central 2009 2009-08-04 /pmc/articles/PMC2750185/ /pubmed/19653888 http://dx.doi.org/10.1186/cc7988 Text en Copyright ©2009 Taori et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Taori, Gopal
Ho, Kwok M
George, Carol
Bellomo, Rinaldo
Webb, Steven AR
Hart, Graeme K
Bailey, Michael J
Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
title Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
title_full Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
title_fullStr Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
title_full_unstemmed Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
title_short Landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
title_sort landmark survival as an end-point for trials in critically ill patients – comparison of alternative durations of follow-up: an exploratory analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750185/
https://www.ncbi.nlm.nih.gov/pubmed/19653888
http://dx.doi.org/10.1186/cc7988
work_keys_str_mv AT taorigopal landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis
AT hokwokm landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis
AT georgecarol landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis
AT bellomorinaldo landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis
AT webbstevenar landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis
AT hartgraemek landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis
AT baileymichaelj landmarksurvivalasanendpointfortrialsincriticallyillpatientscomparisonofalternativedurationsoffollowupanexploratoryanalysis